Olberg HK, et al. - The authors performed this study to examine the influence of immunomodulatory therapies on the antibody response and seroprotection rates in multiple sclerosis (MS) patients immunized with seasonal influenza vaccine in 2012/2013 compared to healthy controls. They proposed that in cases of insufficient protection, MS patients receiving fingolimod or natalizumab ought to be considered for a second dose of the vaccine. The outcomes further showed that new immunomodulatory treatment regimens needed to be systematically assessed for their influence on influenza-specific vaccine responses.